Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorović V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, Wetter JB, Paulsboe SE, Sun Q, Gerstein CE, Medina L, Sielaff B, Sadhukhan R, Stockmann H, Richardson PL, Qiu W, Argiriadi MA, Henry RF, Herold JM, Shotwell JB, McGaraughty SP, Honore P, Gopalakrishnan SM, Sun CC, Scott VE.

Sci Rep. 2019 Jun 24;9(1):9089. doi: 10.1038/s41598-019-45626-w.

2.

Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses.

Slivka PF, Hsieh CL, Lipovsky A, Pratt SD, Locklear J, Namovic MT, McDonald HA, Wetter J, Edelmayer R, Hu M, Murphy E, Domanus M, Lu C, Duggan R, King J, Scott VE, Donnelly-Roberts D, Slavin A, Gopalakrishnan S, Chung N, Goedken ER.

ACS Chem Biol. 2019 May 17;14(5):857-872. doi: 10.1021/acschembio.8b00260. Epub 2019 Apr 15.

PMID:
30938974
3.

Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation.

Wang Y, Edelmayer R, Wetter J, Salte K, Gauvin D, Leys L, Paulsboe S, Su Z, Weinberg I, Namovic M, Gauld SB, Honore P, Scott VE, McGaraughty S.

Sci Rep. 2019 Mar 29;9(1):5310. doi: 10.1038/s41598-019-41655-7.

4.

IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.

Su Z, Paulsboe S, Wetter J, Salte K, Kannan A, Mathew S, Horowitz A, Gerstein C, Namovic M, Todorović V, Seagal J, Edelmayer RM, Viner M, Rinaldi L, Zhou L, Leys L, Huang S, Wang L, Sadhukhan R, Honore P, McGaraughty S, Scott VE.

Exp Dermatol. 2019 Feb;28(2):113-120. doi: 10.1111/exd.13841. Epub 2018 Dec 21.

PMID:
30417427
5.

Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.

Judge RA, Vasudevan A, Scott VE, Simler GH, Pratt SD, Namovic MT, Putman CB, Aguirre A, Stoll VS, Mamo M, Swann SI, Cassar SC, Faltynek CR, Kage KL, Boyce-Rustay JM, Hobson AD.

Chembiochem. 2018 Mar 16;19(6):613-621. doi: 10.1002/cbic.201700547. Epub 2018 Jan 30.

PMID:
29314498
6.

Offering a forage crop at pasture did not adversely affect voluntary cow traffic or milking visits in a pasture-based automatic milking system.

Scott VE, Kerrisk KL, Garcia SC.

Animal. 2016 Mar;10(3):500-7. doi: 10.1017/S1751731115002244. Epub 2015 Nov 16.

PMID:
26567465
7.

Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.

Zhang Q, Xia Z, Joshi S, Scott VE, Jarvis MF.

ACS Med Chem Lett. 2015 Apr 28;6(6):641-4. doi: 10.1021/acsmedchemlett.5b00023. eCollection 2015 Jun 11.

8.

Animal behavior and pasture depletion in a pasture-based automatic milking system.

Lyons NA, Kerrisk KL, Dhand NK, Scott VE, Garcia SC.

Animal. 2014 Sep;8(9):1506-15. doi: 10.1017/S1751731114001190. Epub 2014 May 22.

PMID:
24849557
9.

A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats.

Jarvis MF, Scott VE, McGaraughty S, Chu KL, Xu J, Niforatos W, Milicic I, Joshi S, Zhang Q, Xia Z.

Biochem Pharmacol. 2014 Jun 15;89(4):536-44. doi: 10.1016/j.bcp.2014.03.015. Epub 2014 Apr 12.

PMID:
24726441
10.

Influence of provision of concentrate at milking on voluntary cow traffic in a pasture-based automatic milking system.

Scott VE, Thomson PC, Kerrisk KL, Garcia SC.

J Dairy Sci. 2014 Mar;97(3):1481-90. doi: 10.3168/jds.2013-7375. Epub 2014 Jan 17.

11.

Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models.

Zhu CZ, Vortherms TA, Zhang M, Xu J, Swensen AM, Niforatos W, Neelands T, Milicic I, Lewis LG, Zhong C, Gauvin D, Mikusa J, Zhan C, Pai M, Roderwald V, Chu KL, Cole EE, Bespalov A, Searle XB, McGaraughty S, Bitner RS, Jarvis MF, Bannon AW, Joshi SK, Scott VE, Lee CH.

J Pain. 2014 Apr;15(4):387.e1-14. doi: 10.1016/j.jpain.2013.12.002. Epub 2013 Dec 25.

PMID:
24374196
12.

Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.

Beebe X, Yeung CM, Darczak D, Shekhar S, Vortherms TA, Miller L, Milicic I, Swensen AM, Zhu CZ, Banfor P, Wetter JM, Marsh KC, Jarvis MF, Scott VE, Schrimpf MR, Lee CH.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4857-61. doi: 10.1016/j.bmcl.2013.06.074. Epub 2013 Jul 4.

PMID:
23876987
13.
14.

Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.

Beebe X, Darczak D, Henry RF, Vortherms T, Janis R, Namovic M, Donnelly-Roberts D, Kage KL, Surowy C, Milicic I, Niforatos W, Swensen A, Marsh KC, Wetter JM, Franklin P, Baker S, Zhong C, Simler G, Gomez E, Boyce-Rustay JM, Zhu CZ, Stewart AO, Jarvis MF, Scott VE.

Bioorg Med Chem. 2012 Jul 1;20(13):4128-39. doi: 10.1016/j.bmc.2012.04.057. Epub 2012 May 4.

PMID:
22626552
15.

An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics.

Swensen AM, Niforatos W, Vortherms TA, Perner RJ, Li T, Schrimpf MR, Scott VE, Lee L, Jarvis MF, McGaraughty S.

Assay Drug Dev Technol. 2012 Dec;10(6):542-50. doi: 10.1089/adt.2011.437. Epub 2012 Mar 19.

PMID:
22428804
16.

Discovery of diphenyl lactam derivatives as N-type calcium channel blockers.

Doherty GA, Bhatia P, Vortherms TA, Marsh KC, Wetter JM, Mack H, Scott VE, Jarvis MF, Stewart AO.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1716-8. doi: 10.1016/j.bmcl.2011.12.100. Epub 2012 Jan 8.

PMID:
22277280
17.

A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats.

Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I, Banfor PN, King A, Zhong C, Simler G, Zhan C, Bratcher N, Boyce-Rustay JM, Zhu CZ, Bhatia P, Doherty G, Mack H, Stewart AO, Jarvis MF.

Biochem Pharmacol. 2012 Feb 1;83(3):406-18. doi: 10.1016/j.bcp.2011.10.019. Epub 2011 Nov 16.

PMID:
22153861
18.

Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE.

Inflamm Res. 2011 Jul;60(7):683-93. doi: 10.1007/s00011-011-0322-9. Epub 2011 Mar 11.

PMID:
21394563
19.

Molecular determinants of species-specific activation or blockade of TRPA1 channels.

Chen J, Zhang XF, Kort ME, Huth JR, Sun C, Miesbauer LJ, Cassar SC, Neelands T, Scott VE, Moreland RB, Reilly RM, Hajduk PJ, Kym PR, Hutchins CW, Faltynek CR.

J Neurosci. 2008 May 7;28(19):5063-71. doi: 10.1523/JNEUROSCI.0047-08.2008.

20.

Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states.

Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, Scott VE, Honore P.

J Pain. 2008 May;9(5):449-56. doi: 10.1016/j.jpain.2008.01.329. Epub 2008 Mar 12.

PMID:
18337184
21.

Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R).

Beebe X, Darczak D, Davis-Taber RA, Uchic ME, Scott VE, Jarvis MF, Stewart AO.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2162-6. doi: 10.1016/j.bmcl.2008.01.052. Epub 2008 Jan 18.

PMID:
18272364
22.

Characterization of human ASIC2a homomeric channels stably expressed in murine Ltk- cells.

Malysz J, Scott VE, Faltynek C, Gopalakrishnan M.

Life Sci. 2008 Jan 2;82(1-2):30-40. Epub 2007 Oct 26.

PMID:
18054963
23.

Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.

Perez-Medrano A, Brune ME, Buckner SA, Coghlan MJ, Fey TA, Gopalakrishnan M, Gregg RJ, Kort ME, Scott VE, Sullivan JP, Whiteaker KL, Carroll WA.

J Med Chem. 2007 Nov 29;50(24):6265-73. Epub 2007 Oct 31.

PMID:
17973362
24.

Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, Richardson PL, Pereda-Lopez A, Uchic ME, Solomon LR, Lake MR, Walter KA, Hajduk PJ, Olejniczak ET.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):7875-80. Epub 2007 Apr 30.

25.

Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597).

Niforatos W, Zhang XF, Lake MR, Walter KA, Neelands T, Holzman TF, Scott VE, Faltynek CR, Moreland RB, Chen J.

Mol Pharmacol. 2007 May;71(5):1209-16. Epub 2007 Feb 21.

PMID:
17314320
26.

Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.

Altenbach RJ, Brune ME, Buckner SA, Coghlan MJ, Daza AV, Fabiyi A, Gopalakrishnan M, Henry RF, Khilevich A, Kort ME, Milicic I, Scott VE, Smith JC, Whiteaker KL, Carroll WA.

J Med Chem. 2006 Nov 16;49(23):6869-87.

PMID:
17154517
27.

Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (TRPA1) antagonists.

Chen J, Lake MR, Sabet RS, Niforatos W, Pratt SD, Cassar SC, Xu J, Gopalakrishnan S, Pereda-Lopez A, Gopalakrishnan M, Holzman TF, Moreland RB, Walter KA, Faltynek CR, Warrior U, Scott VE.

J Biomol Screen. 2007 Feb;12(1):61-9. Epub 2006 Nov 12.

PMID:
17099245
28.

A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.

Kage KL, Richardson PL, Traphagen L, Severin J, Pereda-Lopez A, Lubben T, Davis-Taber R, Vos MH, Bartley D, Walter K, Harlan J, Solomon L, Warrior U, Holzman TF, Faltynek C, Surowy CS, Scott VE.

J Neurosci Methods. 2007 Mar 30;161(1):47-54. Epub 2006 Nov 2.

PMID:
17083980
29.

Distribution and functional characterization of human Nav1.3 splice variants.

Thimmapaya R, Neelands T, Niforatos W, Davis-Taber RA, Choi W, Putman CB, Kroeger PE, Packer J, Gopalakrishnan M, Faltynek CR, Surowy CS, Scott VE.

Eur J Neurosci. 2005 Jul;22(1):1-9.

PMID:
16029190
30.

How equitable is the scaling up of HIV service provision in South Africa?

Scott VE, Chopra M, Conrad L, Ntuli A.

S Afr Med J. 2005 Feb;95(2):109-13.

31.

An efficient SNP system for mouse genome scanning and elucidating strain relationships.

Petkov PM, Ding Y, Cassell MA, Zhang W, Wagner G, Sargent EE, Asquith S, Crew V, Johnson KA, Robinson P, Scott VE, Wiles MV.

Genome Res. 2004 Sep;14(9):1806-11.

32.

In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892.

Gopalakrishnan M, Buckner SA, Shieh CC, Fey T, Fabiyi A, Whiteaker KL, Davis-Taber R, Milicic I, Daza AV, Scott VE, Castle NA, Printzenhoff D, London B, Turner SC, Carroll WA, Sullivan JP, Coghlan MJ, Brune ME.

Br J Pharmacol. 2004 Sep;143(1):81-90. Epub 2004 Aug 9.

33.

Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury.

Zhang XF, Zhu CZ, Thimmapaya R, Choi WS, Honore P, Scott VE, Kroeger PE, Sullivan JP, Faltynek CR, Gopalakrishnan M, Shieh CC.

Brain Res. 2004 May 29;1009(1-2):147-58.

PMID:
15120592
34.

Functional analysis of large conductance Ca2(+)-activated K(+) channels: ion flux studies by atomic absorption spectrometry.

Parihar AS, Groebe DR, Scott VE, Feng J, Zhang XF, Warrior U, Gopalakrishnan M, Shieh CC.

Assay Drug Dev Technol. 2003 Oct;1(5):647-54.

PMID:
15090237
35.

Structure-activity studies for a novel series of tricyclic dihydropyridopyrazolones and dihydropyridoisoxazolones as K(ATP) channel openers.

Drizin I, Altenbach RJ, Buckner SA, Whiteaker KL, Scott VE, Darbyshire JF, Jayanti V, Henry RF, Coghlan MJ, Gopalakrishnan M, Carroll WA.

Bioorg Med Chem. 2004 Apr 15;12(8):1895-904.

PMID:
15051058
36.

Characterization of human urinary bladder KATP channels containing SUR2B splice variants expressed in L-cells.

Scott VE, Davis-Taber RA, Silvia C, Hoogenboom L, Choi W, Kroeger P, Whiteaker KL, Gopalakrishnan M.

Eur J Pharmacol. 2004 Jan 12;483(2-3):195-205.

PMID:
14729107
37.

Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.

Perez-Medrano A, Buckner SA, Coghlan MJ, Gregg RJ, Gopalakrishnan M, Kort ME, Lynch JK, Scott VE, Sullivan JP, Whiteaker KL, Carroll WA.

Bioorg Med Chem Lett. 2004 Jan 19;14(2):397-400.

PMID:
14698167
38.

[125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: characterization and pharmacology of binding.

Davis-Taber R, Molinari EJ, Altenbach RJ, Whiteaker KL, Shieh CC, Rotert G, Buckner SA, Malysz J, Milicic I, McDermott JS, Gintant GA, Coghlan MJ, Carroll WA, Scott VE, Gopalakrishnan M.

Mol Pharmacol. 2003 Jul;64(1):143-53.

PMID:
12815170
39.

Structure-activity relationship of a novel class of naphthyl amide KATP channel openers.

Turner SC, Carroll WA, White TK, Brune ME, Buckner SA, Gopalakrishnan M, Fabiyi A, Coghlan MJ, Scott VE, Castle NA, Daza AV, Milicic I, Sullivan JP.

Bioorg Med Chem Lett. 2003 May 19;13(10):1741-4.

PMID:
12729655
40.

Pharmacological characterization of a 1,4-dihydropyridine analogue, 9-(3,4-dichlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydro-1,8(2H,5H)-acridinedione (A-184209) as a novelK(ATP) channel inhibitor.

Gopalakrishnan M, Miller TR, Buckner SA, Milicic I, Molinari EJ, Whiteaker KL, Davis-Taber R, Scott VE, Cassidy C, Sullivan JP, Carroll WA.

Br J Pharmacol. 2003 Jan;138(2):393-9.

41.

(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization.

Gopalakrishnan M, Buckner SA, Whiteaker KL, Shieh CC, Molinari EJ, Milicic I, Daza AV, Davis-Taber R, Scott VE, Sellers D, Chess-Williams R, Chapple CR, Liu Y, Liu D, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ.

J Pharmacol Exp Ther. 2002 Oct;303(1):379-86.

PMID:
12235274
42.

Fluorescence-based functional assay for sarcolemmal ATP-sensitive potassium channel activation in cultured neonatal rat ventricular myocytes.

Whiteaker KL, Davis-Taber R, Scott VE, Gopalakrishnan M.

J Pharmacol Toxicol Methods. 2001 Jul-Aug;46(1):45-50.

PMID:
12164259
43.

Use of coisogenic host blastocysts for efficient establishment of germline chimeras with C57BL/6J ES cell lines.

Schuster-Gossler K, Lee AW, Lerner CP, Parker HJ, Dyer VW, Scott VE, Gossler A, Conover JC.

Biotechniques. 2001 Nov;31(5):1022-4, 1026.

44.

Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators.

Whiteaker KL, Gopalakrishnan SM, Groebe D, Shieh CC, Warrior U, Burns DJ, Coghlan MJ, Scott VE, Gopalakrishnan M.

J Biomol Screen. 2001 Oct;6(5):305-12.

PMID:
11689130
45.

Molecular characterization of human SUR2-containing K(ATP) channels.

Davis-Taber R, Choi W, Feng J, Hoogenboom L, McNally T, Kroeger P, Shieh CC, Simmer R, Brioni JD, Sullivan JP, Gopalakrishnan M, Scott VE.

Gene. 2000 Oct 3;256(1-2):261-70.

PMID:
11054556
46.

Pharmacological and molecular analysis of ATP-sensitive K(+) channels in the pig and human detrusor.

Buckner SA, Milicic I, Daza A, Davis-Taber R, Scott VE, Sullivan JP, Brioni JD.

Eur J Pharmacol. 2000 Jul 21;400(2-3):287-95.

PMID:
10988346
47.

Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells.

Gopalakrishnan M, Molinari EJ, Shieh CC, Monteggia LM, Roch JM, Whiteaker KL, Scott VE, Sullivan JP, Brioni JD.

Br J Pharmacol. 2000 Apr;129(7):1323-32.

48.

Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line.

Miller TR, Taber RD, Molinari EJ, Whiteaker KL, Monteggia LM, Scott VE, Brioni JD, Sullivan JP, Gopalakrishnan M.

Eur J Pharmacol. 1999 Apr 9;370(2):179-85. Review.

PMID:
10323267
49.

Characterization of the ATP-sensitive potassium channels (KATP) expressed in guinea pig bladder smooth muscle cells.

Gopalakrishnan M, Whiteaker KL, Molinari EJ, Davis-Taber R, Scott VE, Shieh CC, Buckner SA, Milicic I, Cain JC, Postl S, Sullivan JP, Brioni JD.

J Pharmacol Exp Ther. 1999 Apr;289(1):551-8.

PMID:
10087049
50.

Overlay and bead assay. Determination of calcium channel subunit interaction domains.

Scott VE, Gurnett CA, Campbell KP.

Methods Mol Biol. 1998;88:71-85. No abstract available.

PMID:
9664299

Supplemental Content

Loading ...
Support Center